CONMED Corporation (CNMD): Price and Financial Metrics


CONMED Corporation (CNMD)

Today's Latest Price: $103.32 USD

2.09 (2.06%)

Updated Nov 23 6:40pm

Add CNMD to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

CNMD Stock Summary

  • CNMD's went public 30.68 years ago, making it older than 84.52% of listed US stocks we're tracking.
  • With a price/earnings ratio of 9,309.77, Conmed Corp P/E ratio is greater than that of about 99.83% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for CNMD is currently 33.96, higher than 87.9% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to Conmed Corp, a group of peers worth examining would be POST, VCEL, WPRT, HPE, and QADB.
  • CNMD's SEC filings can be seen here. And to visit Conmed Corp's official web site, go to www.conmed.com.

CNMD Stock Price Chart Interactive Chart >

Price chart for CNMD

CNMD Price/Volume Stats

Current price $103.32 52-week high $116.81
Prev. close $101.23 52-week low $37.66
Day low $102.36 Volume 320,200
Day high $104.48 Avg. volume 363,324
50-day MA $84.57 Dividend yield 0.77%
200-day MA $78.51 Market Cap 2.96B

CONMED Corporation (CNMD) Company Bio


CONMED Corporation is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The company was founded in 1970 and is based in Utica, New York.

CNMD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$103.32$23.78 -77%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Conmed Corp. To summarize, we found that Conmed Corp ranked in the 18th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 76.5%. In terms of the factors that were most noteworthy in this DCF analysis for CNMD, they are:

  • Conmed Corp's weighted average cost of capital (WACC) is 9%; for context, that number is higher than 66.29% of tickers in our DCF set.
  • CNMD's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 10%; for context, that number is higher than 66.29% of tickers in our DCF set.
  • Relative to other stocks in its sector (Healthcare), Conmed Corp has a reliance on debt greater than 62.91% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-77%
1%-77%
2%-77%
3%-76%
4%-76%
5%-76%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CNMD, try LMNX, CNC, MOH, NUVA, and GMED.


CNMD Latest News Stream


Event/Time News Detail
Loading, please wait...

CNMD Latest Social Stream


Loading social stream, please wait...

View Full CNMD Social Stream

Latest CNMD News From Around the Web

Below are the latest news stories about Conmed Corp that investors may wish to consider to help them evaluate CNMD as an investment opportunity.

CONMED Corporation to Present at the Morgan Stanley Global Healthcare Conference

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, President, Chief Executive Officer and Chair of the Board, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference at 3:30 p.m. ET on Wednesday, September 16, 2020. A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.conmed.com

Business Wire | September 3, 2020

Global ENT Endoscopic Surgery Devices Market (2019 to 2024) - Featuring Acclarent, Conmed & Entellus Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global ENT Endoscopic Surgery Devices Market" report has been added to ResearchAndMarkets.com's offering. This report was developed using extensive primary and secondary research by the publisher's analysts. Data from proprietary databases, proprietary market reports, company reports, import/export databases, and secondary data sources on medical device markets were used to develop estimates of 2019 worldwide market size by product segment, ASPs, sales, and market

Business Wire | August 28, 2020

Impact of COVID-19 on the Surgical Energy Generators Market 2020-2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Surgical Energy Generators (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This market model discusses in detail the impact of COVID-19 on Surgical Energy Generators market for the year 2020 and beyond. Companies Mentioned Medtronic plc Ethicon Inc. Olympus Corp. Conmed Corp. Stryker Corp. ERBE Elektromedizin GmbH Each of the covered 39 country's color-coded and full

Business Wire | August 17, 2020

CONMED Corporation Announces Quarterly Cash Dividend

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2020 to all shareholders of record as of September 15, 2020. About CONMED Corporation CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedi

Business Wire | August 13, 2020

Endoscopy Fluid Management Systems Market, 2020-2030: Implications of the COVID-19 Pandemic - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Endoscopy Fluid Management Systems (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This market model discusses in detail the impact of COVID-19 on Endoscopy Fluid Management Systems market for the year 2020 and beyond. Companies Mentioned Stryker Corporation B. Braun Melsungen AG Hologic Inc. Olympus Corp. ConMed Corporation KARL STORZ GmbH & Co. KG W.O.M. World

Business Wire | August 12, 2020

Read More 'CNMD' Stories Here

CNMD Price Returns

1-mo 22.32%
3-mo 21.66%
6-mo 41.57%
1-year -10.47%
3-year 99.16%
5-year 156.91%
YTD -6.86%
2019 75.71%
2018 27.39%
2017 17.33%
2016 2.19%
2015 -0.42%

CNMD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full CNMD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0076 seconds.